These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 23749295)
1. Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. Catzola V; Battaglia A; Buzzonetti A; Fossati M; Scuderi F; Fattorossi A; Evoli A J Neurol; 2013 Aug; 260(8):2163-5. PubMed ID: 23749295 [No Abstract] [Full Text] [Related]
3. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. Stein B; Bird SJ J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497 [No Abstract] [Full Text] [Related]
4. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis. Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503 [No Abstract] [Full Text] [Related]
5. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Hain B; Jordan K; Deschauer M; Zierz S Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216 [TBL] [Abstract][Full Text] [Related]
7. Rituximab in refractory MuSK antibody myasthenia gravis. Thakre M; Inshasi J; Marashi M J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964 [No Abstract] [Full Text] [Related]
8. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis. Burusnukul P; Brennan TD; Cupler EJ J Clin Neuromuscul Dis; 2010 Dec; 12(2):85-7. PubMed ID: 21386776 [TBL] [Abstract][Full Text] [Related]
9. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab. Weger S; Appendino JP; Clark IH J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277 [TBL] [Abstract][Full Text] [Related]
10. Editorial: Advances in Autoimmune Myasthenia Gravis. Punga AR; Kusner L; Berrih-Aknin S; Le Panse R Front Immunol; 2020; 11():1688. PubMed ID: 32983085 [No Abstract] [Full Text] [Related]
11. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis. Zingariello CD; Elder ME; Kang PB Pediatr Neurol; 2020 Oct; 111():40-43. PubMed ID: 32951658 [TBL] [Abstract][Full Text] [Related]
12. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment. Lau AY; Chan AY; Mok VC Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832 [TBL] [Abstract][Full Text] [Related]
13. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis. Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611 [TBL] [Abstract][Full Text] [Related]
14. Rituximab in the management of refractory myasthenia gravis. Zebardast N; Patwa HS; Novella SP; Goldstein JM Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027 [TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis with antibodies to MuSK: an update. Evoli A; Alboini PE; Damato V; Iorio R; Provenzano C; Bartoccioni E; Marino M Ann N Y Acad Sci; 2018 Jan; 1412(1):82-89. PubMed ID: 29266255 [TBL] [Abstract][Full Text] [Related]